Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2168-4804
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021 ; volume:56 ; number:5 ; day:28 ; month:7 ; year:2022 ; pages:698-703 ; date:9.2022
Therapeutic innovation & regulatory science ; 56, Heft 5 (28.7.2022), 698-703, 9.2022
- Creator
-
Beakes-Read, Ginny
Neisser, Madison
Frey, Patrick
Guarducci, Mara
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s43441-022-00430-z
- URN
-
urn:nbn:de:101:1-2022102122554352700166
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Beakes-Read, Ginny
- Neisser, Madison
- Frey, Patrick
- Guarducci, Mara
- SpringerLink (Online service)
Other Objects (12)
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA efficiency for approval process of COVID-19 therapeutics
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
December: December
December: December
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
![[2 December - 30 December]](https://iiif.deutsche-digitale-bibliothek.de/image/2/96209dd6-8bd1-4148-b63b-5b32fb6cf17e/full/!306,450/0/default.jpg)
[2 December - 30 December]
10. December-21. December
21. December - 31. December
11. December - 20. December
1. December - 10. December
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA efficiency for approval process of COVID-19 therapeutics
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
December: December
December: December
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
[2 December - 30 December]
10. December-21. December
21. December - 31. December
11. December - 20. December
1. December - 10. December
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA efficiency for approval process of COVID-19 therapeutics
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
December: December
December: December
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
[2 December - 30 December]
10. December-21. December
21. December - 31. December
11. December - 20. December